Popularity #2,205Earnings are out
AnaptysBio (ANAB)
Manages Jemperli and imsidolimab royalties through GSK and Vanda partnerships.
$51.47
vs last close−2.45 (−4.54%)
Something off on this page? Send us feedback.
Next report
Nov 3, 26
estimated · in 41 days
EPS estimate
−$0.06
Revenue estimate
$22.6M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Mar '26May '26Sep '26Nov '26
Reported−$0.72−$1.28−$1.34$0.52$1.58−$1.84$5.11Pending
Estimate−$1.55−$1.30−$1.50−$1.06$0.89−$0.32−$0.47−$0.06
Surprise+53.5%+1.5%+10.7%+149.1%+77.5%−475.0%+1,198.9%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Mar '26May '26Sep '26Nov '26
Reported$43.1M$27.8M$22.3M$76.3M$108.2M$25.6M$27.5MPending
Estimate$7.8M$15.3M$11.7M$21.9M$87.0M$18.9M$14.1M$22.6M
Surprise+453.9%+81.8%+90.5%+248.2%+24.4%+35.5%+95.5%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | $1.27 | — | — |
| Sep 2027 | $0.32 | — | — |
| Jun 2027 | $0.07 | — | — |
| Mar 2027 | −$0.06 | — | — |
| Dec 2026 | $0.02 | — | — |
| Nov 2026 | −$0.06 | — | — |
| Sep 2026 | −$0.47 | $5.11 | +1,198.9% |
| May 2026 | −$0.32 | −$1.84 | −475.0% |
| Mar 2026 | $0.89 | $1.58 | +77.5% |
| Nov 2025 | −$1.06 | $0.52 | +149.1% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Jan 2017 | |||
| Jun 2016 | |||
| Mar 2016 | |||
| Dec 2015 | |||
| Sep 2015 | |||
| Jun 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | $1.27 | — | — | $116.7M | — | — | — |
| Sep 2027 | $0.32 | — | — | $75.2M | — | — | — |
| Jun 2027 | $0.07 | — | — | $5.1M | — | — | — |
| Mar 2027 | −$0.06 | — | — | $18.0M | — | — | — |
| Dec 2026 | $0.02 | — | — | $21.0M | — | — | — |
| Nov 3, 2026 | −$0.06 | — | — | $22.6M | — | — | — |
| Sep 21, 2026 | −$0.47 | $5.11 | +1,198.9% | $14.1M | $27.5M | +95.5% | −1.8% |
| May 12, 2026 | −$0.32 | −$1.84 | −475.0% | $18.9M | $25.6M | +35.5% | −3.5% |
| Mar 3, 2026 | $0.89 | $1.58 | +77.5% | $87.0M | $108.2M | +24.4% | −3.8% |
| Nov 4, 2025 | −$1.06 | $0.52 | +149.1% | $21.9M | $76.3M | +248.2% | −3.6% |
| Aug 7, 2025 | |||||||
| May 5, 2025 | |||||||
| Feb 27, 2025 | |||||||
| Nov 5, 2024 | |||||||
| Aug 5, 2024 | |||||||
| May 9, 2024 | |||||||
| Mar 12, 2024 | |||||||
| Nov 2, 2023 | |||||||
| Aug 7, 2023 | |||||||
| May 11, 2023 | |||||||
| Mar 1, 2023 | |||||||
| Nov 8, 2022 | |||||||
| Aug 8, 2022 | |||||||
| May 4, 2022 | |||||||
| Mar 7, 2022 | |||||||
| Nov 4, 2021 | |||||||
| Aug 9, 2021 | |||||||
| May 4, 2021 | |||||||
| Feb 25, 2021 | |||||||
| Nov 4, 2020 | |||||||
| Aug 10, 2020 | |||||||
| May 6, 2020 | |||||||
| Mar 2, 2020 | |||||||
| Nov 8, 2019 | |||||||
| Aug 8, 2019 | |||||||
| May 7, 2019 | |||||||
| Feb 28, 2019 | |||||||
| Nov 8, 2018 | |||||||
| Aug 7, 2018 | |||||||
| May 8, 2018 | |||||||
| Mar 5, 2018 | |||||||
| Nov 7, 2017 | |||||||
| Aug 10, 2017 | |||||||
| May 11, 2017 | |||||||
| Mar 8, 2017 | |||||||
| Jan 26, 2017 | |||||||
| Jun 30, 2016 | |||||||
| Mar 31, 2016 | |||||||
| Dec 31, 2015 | |||||||
| Sep 30, 2015 | |||||||
| Jun 30, 2015 |